Business Context and Reporting Period
This Form 8-K Current Report was filed by IMMUNIC, INC. on December 18, 2023. The filing discloses amendments to service agreements for key members of the management team (Vorstand) of Immunic AG, a wholly-owned subsidiary of the Company. The amendments extend the tenure of these executives through December 31, 2026, and update their compensation packages.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document focuses exclusively on executive compensation arrangements.
Material Changes and Executive Compensation
Effective January 1, 2024, the following compensation changes were implemented for the management team of Immunic AG:
- Dr. Daniel Vitt (CEO and President):
- Annual Salary: EUR 565,653.
- Targeted Yearly Bonus: Up to EUR 311,573.
- Term Extension: Through December 31, 2026.
- Equity: Accelerated vesting of stock options upon termination under specified circumstances; one-year exercise period post-termination.
- Dr. Andreas Muehler (Chief Medical Officer):
- Immunic AG Agreement: Annual salary of EUR 231,825; targeted bonus up to EUR 92,730. Term extended to December 31, 2026. Includes accelerated stock option vesting provisions.
- Immunic, Inc. Agreement: Annual salary of $250,000 USD; annual bonus of at least 40% of base salary. Dr. Muehler will dedicate approximately 50% of his time to Immunic, Inc. and 50% to Immunic AG.
- Dr. Hella Kohlhof (Chief Scientific Officer):
- Annual Salary: EUR 403,375.
- Targeted Yearly Bonus: Up to EUR 161,350.
- Term Extension: Through December 31, 2026.
- Equity: Accelerated vesting of stock options upon termination under specified circumstances; one-year exercise period post-termination.
Guidance, Outlook, and Risks
The filing does not provide financial guidance, operational outlook, or discuss specific business risks. The primary contingency noted is the conditionality of the accelerated stock option vesting, which requires the provision of post-employment assistance with the transition of duties.
Investor Verification Checklist
- Verify the total annual cash compensation obligations for the executive team in both EUR and USD.
- Review the specific performance targets required to achieve the targeted bonuses for Dr. Vitt, Dr. Muehler, and Dr. Kohlhof.
- Examine the full text of the Fifth Addendums (Exhibits 10.1, 10.2, 10.4) and the Muehler Employment Agreement (Exhibit 10.3) to understand the specific "specified circumstances" triggering accelerated stock option vesting.
- Confirm the allocation of Dr. Muehler's time between the parent company and the German subsidiary to assess potential conflicts of interest or resource allocation.